Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
144.98
+1.98 (1.38%)
Sep 21, 2026, 4:00 PM EDT - Market closed
Protagonist Therapeutics Employees
Protagonist Therapeutics had 141 employees as of June 30, 2026. The number of employees increased by 11 or 8.46% compared to the same quarter last year.
Employees
141
Change
11
Growth
8.46%
Revenue / Employee
$1,999,943
Profits / Employee
$588,007
Market Cap
9.38B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 141 | 11 | 8.46% |
| Mar 31, 2026 | 131 | 7 | 5.65% |
| Dec 31, 2025 | 132 | 6 | 4.76% |
| Sep 30, 2025 | 128 | 2 | 1.59% |
| Jun 30, 2025 | 130 | 5 | 4.00% |
| Mar 31, 2025 | 124 | 0 | - |
| Dec 31, 2024 | 126 | 14 | 12.50% |
| Sep 30, 2024 | 126 | 15 | 13.51% |
| Jun 30, 2024 | 125 | 19 | 17.92% |
| Mar 31, 2024 | 124 | 21 | 20.39% |
| Dec 31, 2023 | 112 | 7 | 6.67% |
| Sep 30, 2023 | 111 | -11 | -9.02% |
| Jun 30, 2023 | 106 | -21 | -16.54% |
| Mar 31, 2023 | 103 | -19 | -15.57% |
| Dec 31, 2022 | 105 | -13 | -11.02% |
| Sep 30, 2022 | 122 | 6 | 5.17% |
| Jun 30, 2022 | 127 | 26 | 25.74% |
| Mar 31, 2022 | 122 | 39 | 46.99% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| Twist Bioscience | 979 |
| Arrowhead Pharmaceuticals | 711 |
| ImmunityBio | 691 |
| Cytokinetics | 673 |
| Vaxcyte | 507 |
| TG Therapeutics | 399 |
| Krystal Biotech | 295 |
PTGX News
- 11 days ago - Protagonist Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 12 days ago - Protagonist Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 13 days ago - Protagonist Therapeutics announces $300M share repurchase program - TheFly
- 13 days ago - Protagonist Therapeutics Announces $300 Million Share Repurchase Program - Accesswire
- 13 days ago - Protagonist Therapeutics Slides: Corporate presentation - Filings
- 19 days ago - Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026 - Accesswire
- 20 days ago - Protagonist Therapeutics price target raised to $190 from $178 at BMO Capital - TheFly
- 20 days ago - Protagonist Therapeutics price target raised to $180 from $153 at Barclays - TheFly